MTOR and urinary bladder carcinoma: This agent also reduced the cellular viability and migration of TSGH-8301 human bladder cancer cells (10 μM, 24 h), which coincided with a reduction in p-PI3K, p-AKT, and p-mTOR (5–10 μM) [28].